Latest Omeros Corp (OMER) Headlines Additional
Post# of 95
Posted On: 03/13/2014 12:38:24 AM
Latest Omeros Corp (OMER) Headlines
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
PR Newswire - Mon Mar 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. In February, Omeros reported positive results from its OMS721 Phase 1 clinical trial and, earlier this month, announced submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial in patients with TMA, including patients with aHUS.
Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
PR Newswire - Thu Mar 06, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the previously reported highest dose and had a similar side-effect profile to those of the lower doses. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds
PR Newswire - Wed Mar 05, 7:52AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which is expected to fund later today. The new credit facility consists of a $32 million term loan, which requires interest-only payments through March 2015. Thereafter, monthly principal and interest payments will be due through the March 2018 maturity date. The company will use a portion of the loan proceeds to repay its obligations under its prior loan and security agreement with Oxford Finance and affiliates, and the remaining net proceeds of approximately $12.6 million will be used for general corporate purposes and working capital.
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 04, 8:06AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at three health care stocks -- ...
Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program
PR Newswire - Tue Mar 04, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin--associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. In the Phase 2 clinical program, Omeros will evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of orphan disorders, including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), that occur in the microcirculation of the body's organs, most commonly the kidney and brain.
Omeros to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference in Boston, Massachusetts next week. The presentation is scheduled for Wednesday, March 5, 2014 at 11:20 a.m. EST.
'Mad Money' Lightning Round: World Wrestling Is a Turnaround Play
at The Street - Tue Feb 25, 5:00AM CST
Cramer prefers Sysco over Cisco and is no fan of CVR partners.
Jim Cramer's 'Mad Money' Recap: The Values Are Out There
at The Street - Mon Feb 24, 7:06PM CST
But there'll be fewer and fewer as time goes on, Cramer says.
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...
Omeros Doses First Patient in a Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:00PM CST
Omeros announced that the first patient has been dosed in a second phase II study on candidate, OMS824
Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
PR Newswire - Wed Feb 19, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/9tz25p/circadian_rhythm) has announced the addition of the "Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013" report to their offering. 'Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Circadian Rhythm Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Circadian Rhythm Sleep Disorders. Scope - A snapshot of the global therapeutic scenario for Circadian Rhythm Sleep Disorders. - A review of the Circadian Rhythm Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Circadian Rhythm Sleep Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Circadian Rhythm Sleep Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles melatonin - Drug Profile Fibrate - Drug Profile PF-4800467 - Drug Profile OPN4 Antagonist - Drug Profile Drug For Circadian Rhythm Sleep Disorders - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Pfizer Inc. Neurim Pharmaceuticals Ltd Orphagen Pharmaceuticals, Inc. Omeros Corporation For more information visit http://www.researchandmarkets.com/research/9t...ian_rhythm About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Additional Data on Omeros' OMS824 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 3:30PM CST
Omeros released additional positive data from its phase I program on OMS824. It is Omeros' lead compound in its phosphodiesterase 10 (PDE10) program.
Today’s Top Biotech Stories: Mallinckrodt, Regeneron, Arena, and Omeros
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 11, 8:00AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
PR Newswire - Tue Feb 11, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70--percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS). These data further support the potential of OMS824 to have a high therapeutic index in the treatment of patients with schizophrenia, Huntington's disease and other cognitive disorders. Omeros is completing a Phase 2a trial evaluating the drug in patients with schizophrenia and will start enrollment in a Phase 2 trial for Huntington's disease this quarter.
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Why Omeros Corporation Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 05, 12:35PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros , a clinical-stage...
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 05, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
Additional Positive Data on Omeros Treatment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Mar 10, 5:50PM CDT
Omeros announced additional positive results from its phase IIa study on OMS824, for the treatment of schizophrenic patients.
Today's Biggest Health Care Stories: Keryx, Omeros, Alexion, and J&J
Leo Sun, The Motley Fool - Motley Fool - Mon Mar 10, 8:43AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at four companies -- Keryx...
Omeros Announces Positive OMS721 Data in Serum from Patients with aHUS
PR Newswire - Mon Mar 10, 6:00AM CDT
Omeros Corporation (NASDAQ: OMER) today announced positive data using OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) program, in ex vivo studies of endothelial activation relevant to the pathophysiology of human atypical hemolytic uremic syndrome (aHUS), a form of thrombotic microangiopathy (TMA). TMAs are a family of rare, debilitating and life-threatening disorders characterized by multiple thrombi (clots) in the microcirculation of the body's organs, most commonly the kidney and brain. In February, Omeros reported positive results from its OMS721 Phase 1 clinical trial and, earlier this month, announced submission of an investigational new drug application to the U.S. Food and Drug Administration (FDA) to initiate a Phase 2 clinical trial in patients with TMA, including patients with aHUS.
Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial
PR Newswire - Thu Mar 06, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor. Patients with schizophrenia were administered a higher dose than had been evaluated in any OMS824 trial, which resulted in approximately 50 percent higher plasma concentrations than did the previously reported highest dose and had a similar side-effect profile to those of the lower doses. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds
PR Newswire - Wed Mar 05, 7:52AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has closed a senior credit facility with Oxford Finance and MidCap Financial, which is expected to fund later today. The new credit facility consists of a $32 million term loan, which requires interest-only payments through March 2015. Thereafter, monthly principal and interest payments will be due through the March 2018 maturity date. The company will use a portion of the loan proceeds to repay its obligations under its prior loan and security agreement with Oxford Finance and affiliates, and the remaining net proceeds of approximately $12.6 million will be used for general corporate purposes and working capital.
Today's Biggest Biotech Stories: Dendreon, AbbVie, and Omeros
Leo Sun, The Motley Fool - Motley Fool - Tue Mar 04, 8:06AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a closer look at three health care stocks -- ...
Omeros Submits IND to Advance OMS721 Phase 2 Clinical Program
PR Newswire - Tue Mar 04, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) an investigational new drug (IND) application to initiate the Phase 2 clinical program for OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin--associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system. In the Phase 2 clinical program, Omeros will evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of orphan disorders, including atypical hemolytic uremic syndrome (aHUS) and thrombotic thrombocytopenic purpura (TTP), that occur in the microcirculation of the body's organs, most commonly the kidney and brain.
Omeros to Present at Cowen and Company 34th Annual Health Care Conference
PR Newswire - Wed Feb 26, 6:00AM CST
Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation, bleeding and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer, is scheduled to present at the Cowen and Company 34th Annual Health Care Conference in Boston, Massachusetts next week. The presentation is scheduled for Wednesday, March 5, 2014 at 11:20 a.m. EST.
'Mad Money' Lightning Round: World Wrestling Is a Turnaround Play
at The Street - Tue Feb 25, 5:00AM CST
Cramer prefers Sysco over Cisco and is no fan of CVR partners.
Jim Cramer's 'Mad Money' Recap: The Values Are Out There
at The Street - Mon Feb 24, 7:06PM CST
But there'll be fewer and fewer as time goes on, Cramer says.
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
Dan Carroll, The Motley Fool - Motley Fool - Sun Feb 23, 3:53PM CST
No industry embraces the boom-or-bust potential of the stock market like the biotech industry. Under-the-radar stocks can produce huge returns for investors from successful drug approvals, milestone achievements, and other events. But which stocks...
Omeros Doses First Patient in a Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 5:00PM CST
Omeros announced that the first patient has been dosed in a second phase II study on candidate, OMS824
Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824
PR Newswire - Wed Feb 19, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.
Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013 Report
M2 - Mon Feb 17, 4:04AM CST
Research and Markets (http://www.researchandmarkets.com/research/9tz25p/circadian_rhythm) has announced the addition of the "Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013" report to their offering. 'Circadian Rhythm Sleep Disorders - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Circadian Rhythm Sleep Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Circadian Rhythm Sleep Disorders. Scope - A snapshot of the global therapeutic scenario for Circadian Rhythm Sleep Disorders. - A review of the Circadian Rhythm Sleep Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Circadian Rhythm Sleep Disorders pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Circadian Rhythm Sleep Disorders Overview Therapeutics Development Clinical Stage Products Early Stage Products Drug Profiles melatonin - Drug Profile Fibrate - Drug Profile PF-4800467 - Drug Profile OPN4 Antagonist - Drug Profile Drug For Circadian Rhythm Sleep Disorders - Drug Profile R&D Progress Featured News & Press Releases Appendix List of Tables List of Figures Companies Mentioned Pfizer Inc. Neurim Pharmaceuticals Ltd Orphagen Pharmaceuticals, Inc. Omeros Corporation For more information visit http://www.researchandmarkets.com/research/9t...ian_rhythm About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Additional Data on Omeros' OMS824 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 3:30PM CST
Omeros released additional positive data from its phase I program on OMS824. It is Omeros' lead compound in its phosphodiesterase 10 (PDE10) program.
Today’s Top Biotech Stories: Mallinckrodt, Regeneron, Arena, and Omeros
Leo Sun, The Motley Fool - Motley Fool - Tue Feb 11, 8:00AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's take a...
Omeros Reports Additional Positive Phase 1 Clinical Data for OMS824 for the Treatment of Cognitive Disorders
PR Newswire - Tue Feb 11, 6:00AM CST
Omeros Corporation (NASDAQ: OMER) today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70--percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS). These data further support the potential of OMS824 to have a high therapeutic index in the treatment of patients with schizophrenia, Huntington's disease and other cognitive disorders. Omeros is completing a Phase 2a trial evaluating the drug in patients with schizophrenia and will start enrollment in a Phase 2 trial for Huntington's disease this quarter.
This Week in Biotech: Sunny, With No Chance of Rain
Sean Williams, The Motley Fool - Motley Fool - Sat Feb 08, 1:05PM CST
With the SPDR S&P Biotech Index up 57% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector. Keeping that in mind, let's have a look at some of the rulings, studies, and companies...
Why Omeros Corporation Shares Jumped
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 05, 12:35PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Omeros , a clinical-stage...
Nasdaq stocks posting largest percentage increases
AP - Wed Feb 05, 12:20PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
(0)
(0)Omeros Corporation (OMER) Stock Research Links
Scroll down for more posts ▼